FDA pulls one generic form of wellbutrin off the market
Research found extended-release Budeprion at 300 mg dose was not equivalent to brand-name version of antidepressant.
(HealthDay)—People taking the antidepressant Wellbutrin now have one less option for a generic version of the drug.
In October, the U.S. Food and Drug Administration recommended that generic Wellbutrin, or bupropion, made by Impax Laboratories and distributed by Teva Pharmaceuticals, be taken off the market, and Impax and Teva have agreed to stop shipping the drug.
The decision is based on an FDA study that found that the extended release (XL) form of bupropion—Budeprion XL—at the 300 milligram (mg) dose was not bioequivalent to brand-name Wellbutrin XL at the same dose, suggesting that it may not be as safe and effective.
The study was published Dec. 5 in the New England Journal of Medicine.
Four other manufacturers make bupropion XL in 300 mg tablets, and patients can still get their prescription filled with these products.
"The other four generic versions of 300 mg extended-release bupropion tablets are not affected by FDA's recent announcement," said FDA spokesperson Sandy Walsh.
Although the agency stated that lack of bioequivalence might only apply to the Impax/Teva product because of its unique formulation, the agency is requesting that the other four manufacturers submit bioequivalence data to the agency by March 2013.
"This kind of result puts a cloud over all of the generic XL [forms of bupropion]," said Dr. David Hellerstein, a professor of psychiatry at Columbia University Medical Center, in New York City.
Companies including Impax/Teva also make a bupropion XL in 150-mg tablets, which are also not affected by the FDA decision.
But even before the FDA decision, Hellerstein avoided any kind of generic bupropion XL. "Patient would complain that generic XL is not the same as brand-name XL—it wears off sooner, it has more side effects," he said. "I tell patients not to go to XL unless you're committed to taking brand name."
For patients who want a less expensive generic, he recommends sustained release (SR) because there does not seem to be a clinical difference between the brand name and generic versions in that form. SR has to be taken twice a day, while XL is taken once a day.
"If it were me and I could afford it and/or my insurance company allowed me to take it, I would err on the side of caution and take the brand name until the generics were proven at the higher doses to be bioequivalent," said Dr. Sheldon Preskorn, a professor of psychiatry at University of Kansas School of Medicine-Wichita.
The FDA decided to study the bioequivalence of bupropion XL 300 mg made by Impax/Teva to the brand-name counterpart because of adverse events that had been reported to the agency since the generic was approved in 2006.
"The adverse event reports we got included loss of antidepressant effect and, in some instances, worsening of depression symptoms, following a switch from the brand name to a generic product," Walsh said.
Some patients also reported that adverse effects associated with bupropion, including headache, fatigue and anxiety, got worse after switching to Impax/Teva's generic version, Walsh added.
About half of these patients said their depressive symptoms and adverse events improved after switching back to Wellbutrin XL 300 mg, according to the FDA.
"Relapsing of major depression is not inconsequential," Preskorn said. "Major depression causes problems with social functioning, work performance and some level of a suicide risk."
For the bioequivalence study, the FDA measured the level of Wellbutrin and bupropion XL 300 mg in the blood of 24 healthy adult volunteers over the course of the day after taking the medications.
The FDA requires the level of generic drug absorbed in the blood to be, on average, within 80 and 125 percent of the level of the brand-name version. However the range of absorption of bupropion XL was only between 77 and 96 percent of the level of Wellbutrin.
The difference in blood concentration between Wellbutrin and bupropion in this study could explain the clinical difference in safety and effectiveness, Preskorn said. "If the concentration is substantially lower or higher, then your concern would be reduced efficacy or greater likelihood of off-target effects," he said.
Although it is unclear why only the generic XL in 300-mg tablets and not in 150-mg tablets, or only the Impax/Teva version of the 300-mg tablets, would lack bioequivalence, it could be because higher doses of the drug have trouble dissolving in the gastrointestinal tract, Preskorn said.
The FDA approved the generic versions of Wellbutrin XL based on the studies demonstrating bioequivalence at the lower, 150-mg dose.
Typically the FDA recommends that makers of generic drugs test the blood concentration of the drug at the highest dose and then extrapolate bioequivalence data for the lower doses based on these findings.
However, in the case of bupropion, the FDA granted a waiver to companies to test the lower dose because of concern that the higher dose could cause seizures in the volunteers, Walsh wrote.
Either way, extrapolating information about safety and efficacy from one dose is usually appropriate, said Dr. Sidney Wolfe, director of the health research group at Public Citizen, a nonprofit consumer advocacy organization based in Washington, D.C.
"For most drugs, there is such a wide difference between the amount that works and the amount that causes trouble that checking out every single dose is not necessary," he said.
However bupropion might be an exception. Ever since it entered the market in 1985, it was known there was a fine line between antidepressant effect and seizure risk, Wolfe said. The FDA knows which drugs have this type of narrow therapeutic window, and for them it might have been better to check out all the doses, he added.
More information: To learn more about depression and treatments, visit the U.S. National Institute of Mental Health.
Journal reference: New England Journal of Medicine
Copyright © 2012 HealthDay. All rights reserved.
- US says Teva antidepressant is ineffective Oct 03, 2012 | not rated yet | 0
- Generic versions of plavix approved May 18, 2012 | not rated yet | 0
- FDA: Zofran 32-mg dose pulled from market Dec 06, 2012 | not rated yet | 0
- Drug approved to treat high blood pressure Apr 13, 2012 | not rated yet | 0
- US approves India's Ranbaxy to make generic Lipitor Dec 01, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
How can there be a term called "intestinal metaplasia" of stomach
11 hours ago Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
- More from Physics Forums - Medical Sciences
More news stories
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Medications 39 minutes ago | not rated yet | 0
Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...
Medications 1 hour ago | not rated yet | 0
Regardless of pain, social class or age, a woman is more likely to be prescribed pain-relieving drugs. A study published in Gaceta Sanitaria (Spanish health scientific journal) affirms that this phenomenon is inf ...
Medications 9 hours ago | not rated yet | 0
A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...
Medications May 20, 2013 | 5 / 5 (1) | 0
A paper recently published in the New England Journal of Medicine and co-written by physicians and scientists at the University of Colorado School of Medicine finds that an important genetic risk factor for pulmonary fibros ...
1 hour ago | not rated yet | 0
Using the Department of Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers have identified a number of biomarkers for inflammatory bowel disease (IBD), which could help with earlier diagnosis and ...
1 hour ago | not rated yet | 0
By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...
1 hour ago | not rated yet | 0
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent ...
1 hour ago | not rated yet | 0
Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...
1 hour ago | 5 / 5 (2) | 0 |
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
7 hours ago | 4 / 5 (4) | 0 |